# EDGAR Filing Document

**Accession Number:** 0001029125
**File Stem:** 0001437749-23-001612
**Filing Date:** 2023-1
**Character Count:** 2674
**Document Hash:** 7ce149a206e4ea3adb3107d133d172c0
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001437749-23-001612.hdr.sgml**: 20230223

**ACCESSION NUMBER**: 0001437749-23-001612

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20230123

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Panbela Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001029125
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 870543922
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 712 VISTA BLVD #305
- **CITY:** WACONIA
- **STATE:** MN
- **ZIP:** 55387
- **BUSINESS PHONE:** 9524791196

**MAIL ADDRESS:**
- **STREET 1:** 712 VISTA BLVD #305
- **CITY:** WACONIA
- **STATE:** MN
- **ZIP:** 55387

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Sun BioPharma, Inc.
- **DATE OF NAME CHANGE:** 20150911

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Cimarron Medical, Inc.
- **DATE OF NAME CHANGE:** 20150602

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CIMARRON SOFTWARE INC
- **DATE OF NAME CHANGE:** 19961217

January 23, 2023

**<u>VIA EDGAR TRANSMISSION</u>**

Division of Corporation Finance

United States Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549-6010

---

| | | |
|:---|:---|:---|
| Attn: | Joshua Gorsky | Joshua Gorsky |
|  | **Re:** | **Panbela Therapeutics, Inc.** |
|  |  | **Registration Statement on Form S-1 (Registration No. 333-268854)** |
|  |  | **<u>Request for Acceleration of Effective Date</u>** |

---

Ladies and gentlemen:

In accordance with Rule 461 under the Securities Act of 1933, as amended (the "*Act*"), Panbela Therapeutics, Inc. (the "*Company*") hereby respectfully requests that the Securities and Exchange Commission (the "*Commission*") take appropriate action to cause the Registration Statement on Form S-1 (File No. 333-268854) (the "*Registration Statement*") to become effective on January 24, 2023, at 5:30 p.m., Eastern Time, or as soon as thereafter possible. The Company hereby acknowledges its responsibilities under the Act as they relate to the proposes public offering of the securities specified in the Registration Statement.

Please direct any questions or comments concerning this request to Joshua L. Colburn of Faegre Drinker Biddle & Reath LLP, counsel to the Company, at +1 (612) 766-8946.

*[Signature Page Follows]*

------

---

| | |
|:---|:---|
| Very truly yours, | Very truly yours, |
| **PANBELA THERAPEUTICS, INC.**  | **PANBELA THERAPEUTICS, INC.**  |
| By: | /s/ Susan Horvath |
| Name:  | Susan Horvath |
| Title: | Chief Financial Officer |

---